Axsome Therapeutics, Inc. Banner Image

Axsome Therapeutics, Inc. has reached its limit for free report views

Work for Axsome Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Axsome Therapeutics, Inc.

  • Ticker AXSM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Axsome Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in New York City, New York
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome’s core CNS product candidate portfolio includesMore five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), treatment resistant depression (TRD), Alzheimer’s disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
Axsome Therapeutics, Inc.

Most Recent Annual Report

Axsome Therapeutics, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Axsome Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports